Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
P2Et extract safety in healthy volunteers
NCT03663881Phase 1Completed
- Sponsor
- Hospital Universitario San Ignacio
- Start
- Apr 2019
- Primary completion
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of P2Et in breast cancer, melanoma and leukemia, sponsored by Hospital Universitario San Ignacio. Primary endpoint: Maximum Tolerated Dose at 12 months. Started Apr 2019; status: completed.
02
Drugs
P2Et
03
Conditions
breast cancermelanomaleukemia
Beyond the preview
Go deeper on NCT03663881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03663881.